Literature DB >> 25227783

Polycystic ovary syndrome and risk of endometrial cancer: a mini-review.

Aytekin Tokmak1, Mahmut Kuntay Kokanali, Ali Irfan Guzel, Aydan Kara, Hasan Onur Topcu, Sabri Cavkaytar.   

Abstract

The polycystic ovary syndrome is the most common endocrinological disorder of reproductive age women with a prevalence of 5 to 8 %. The most common diagnostic criteria used for polycystic ovary syndrome are oligo- or an-ovulation, clinical and/ or biochemical signs of hyperandrogenism and polycystic ovaries. Hyperandrogenism results in increased estrogen levels and lack of cyclic progesterone due to anovulation and persistent stimulation of the endometrium may lead to endometrial hyperplasia or adenocarcinoma development. In this mini review, we aimed to evaluate the possible relationship between polycystic ovary syndrome and endometrial cancer.

Entities:  

Mesh:

Year:  2014        PMID: 25227783     DOI: 10.7314/apjcp.2014.15.17.7011

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

Review 1.  Insulin, insulin receptors, and cancer.

Authors:  R Vigneri; I D Goldfine; L Frittitta
Journal:  J Endocrinol Invest       Date:  2016-07-01       Impact factor: 4.256

2.  Is anti-Mullerian hormone a good diagnostic marker for adolescent and young adult patients with Polycystic ovary syndrome?

Authors:  Aytekin Tokmak; Hakan Timur; Rıfat Taner Aksoy; Mehmet Çınar; Nafiye Yılmaz
Journal:  Turk J Obstet Gynecol       Date:  2015-12-15

3.  Cadmium exposure and endometrial cancer risk: A large midwestern U.S. population-based case-control study.

Authors:  Jane A McElroy; Robin L Kruse; James Guthrie; Ronald E Gangnon; J David Robertson
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

4.  Evaluation of Serum Human Epididymis Protein 4 Levels in Women with Polycystic Ovary Syndrome.

Authors:  Necati Hancerliogullari; Aytekin Tokmak; Meryem Kuru Pekcan; Aysegul Oksuzoglu; Tuba Candar; Yaprak Ustun
Journal:  Cureus       Date:  2019-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.